Comparison of a pediatric practice-based therapy and an interdisciplinary ambulatory treatment in social pediatric centers for migraine in children: a nation-wide randomized-controlled trial in Germany: “moma – modules on migraine activity”

Mirjam N. Landgraf1*, Florian Heinen1, Lucia Gerstl1, Christine Kainz1, Ruth Ruscheweyh2, Andreas Straube2, Joerg Scheidt3, Sabine von Mutius4, Viola Obermeier4 and Ruediger von Kries4

Abstract

Background: Migraine is common in childhood, peaks in adolescents and persists into adulthood in at least 40% of patients. There is need for early interventions to improve the burden of disease and, if possible, reduce chronification. The aim of the project is to compare two types of ambulatory treatment strategies regarding their effect on headache days and quality of life in 6 to 11 year old children with migraine: 1) the routine care in pediatricians’ practices (intervention group A) and 2) a structured interdisciplinary multimodal intervention administered at social pediatric centers (intervention group B).

Methods: The study is a nation-wide cluster-randomized study. Based on the postal codes the regions are randomly assigned to the two intervention-strategies. Children with migraine are recruited in the pediatric practices, as common outpatient-care in the German health-care system. Parents rate headache frequency, intensity and acute medication intake at a daily basis via a digital smartphone application specifically designed for the study. Migraine-related disability and quality of life are assessed every 3 months. Study duration is 9 months for every participant: 3 months of baseline at the pediatric practice (both groups); 3 months of intervention at the pediatric practice (intervention group A) or at the social pediatric center (intervention group B), respectively; 3 months of follow-up at the pediatric practice (both groups).
Discussion: Results of the planned comparison of routine care in pediatric practices and interdisciplinary social pediatric centers will be relevant for treatment of children with migraine, both for the individual and for the health care system.

Trial registration: The study was approved by the ethics committee at the Ludwig-Maximilians-University Munich (number 18–804) and was retrospectively registered on 27 April 2021 in the WHO approved German Clinical Trials Register (number DRKS00016698).

Keywords: Migraine, Children, Intervention, Interdisciplinary, Pediatric practice

Background
Migraine is a chronic disease often starting in childhood. The Barmer health insurance company dataset, which is covering 11% of all German policyholders, showed that in 2015 approximately 1% of all children received a diagnosis of migraine already at the age of primary school (6 to 11 years of age) [1]. In patients with migraine diagnosed at the age of 7 years, migraine persists into adulthood in 65% of the affected females and 21% of the affected males [2].

The Barmer insurance data also reveal that only half of the primary school children diagnosed with migraine got appropriate medication e.g. NSAID, but 2.1% were at least once in inpatient treatment for migraine. Only 6% of the affected children received an interdisciplinary therapy at a social pediatric center (unpublished data). Social pediatric centers are regional neuropediatric centers offering interdisciplinary treatment for children with chronic diseases. They belong to the customary care institutions in Germany.

It has repeatedly been shown that interdisciplinary treatment is effective in adult patients with migraine: e.g., in one study 42.5% of patients achieved a reduction of headache days of more than 50% even in the long term [3] and in another study, the number of headache days was significantly reduced from 13.8 ± 7.6 to 8.2 ± 6.2 [4]. Comparisons with standard basic care have shown superiority of multimodal treatment [5, 6].

Studies about the efficacy of multimodal treatment in young children with migraine do not exist so far. Children with migraine have a shorter migraine history and less comorbidities, such as other pain syndromes or psychiatric disorders, than adult migraine patients. Therefore, an early interdisciplinary multimodal treatment in young children may lead to an even better outcome in comparison to adults and may prevent the establishing of co-morbidities in the long term. Effective elements of treatment seem to include counselling on life style factors [7, 8] and psychotherapeutic [9] and physiotherapeutic measures [9, 10]. These interdisciplinary multimodal approaches are a distinguishing feature of German social pediatric centers.

Therefore, we designed an interdisciplinary multimodal intervention for treatment of pediatric migraine in social pediatric centers and a randomized controlled study to evaluate its effectiveness compared with standard basic pediatric care over a 9 months interval (elements of the interdisciplinary intervention: see 2.3. Study Design).

The aim of the presented study is to evaluate if an early intervention in young children at the time migraine has just started leads to a reduction of headache days and headache intensity as well as to a lower intake of analgesics and to an amelioration of quality of life.

Methods/design
Patient involvement
Children with migraine are treated in pediatric practices and social pediatric centers in Germany. As interdisciplinary multimodal treatment showed superior effects in the care of adults with migraine, we included pediatric, psychological and physiotherapeutic modules in the treatment of children with migraine in our clinical work at the social pediatric center in Munich. The satisfaction with this treatment of both children with migraine and their parents thereby ameliorated in a significant way. Based on this experience, we developed the patient-centered, structured, interdisciplinary multimodal intervention “moma – modules on migraine activity”, presented in this protocol. Nevertheless, pediatricians in practice are the standard basic pediatric care for children with migraine in Germany and are often very effective. Thus, we chose treatment in pediatric practices as comparative intervention strategy in our study design. Another aspect of patient involvement in the study design was that, to our clinical experience, the acceptance of treatment support via digital applications is high among parents in the neuropediatric field. Therefore, we developed the “moma app” for smartphones to facilitate the documentation of headache symptoms for the parents of participating children with migraine. The results of the study will be disseminated not only in scientific journals but also in public media to attain transparency for patients and their parents about the effectiveness of different treatment strategies for children with migraine.
Selection of sample
Children between 6 and 11 years of age with migraine with a statutory health insurance (approx. 90% of the population) and whose parents consent to participation are eligible for the study. Children are recruited by their pediatricians in practice. The pediatrician diagnoses migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) [11], with the help of a standardized, electronic migraine checklist that was developed for the study.

Inclusion criteria are as follows:
- Age 6 to 11 years
- Diagnosis of migraine (according to the International Classification of Diseases ICD-10, classification numbers G43.x), based on the International Classification of Headache Disorders (ICHD-3) [11] adapted to children (allowing shorter headache duration of 2 to 72 h, and bilateral instead of unilateral headache)
- History of migraine for at least 3 months
- At least 3 headache days in the last 3 months
- Migraine prophylactic medication (beta-blocker, amitriptyline, topiramate) allowed if kept constant for the duration of the study

Exclusion criteria are:
- Mental retardation (IQ < 70)
- Severe somatic or psychological, acute or chronic disease except headache
- Familiar hemiplegic migraine (genetically confirmed)
- Children will be excluded after the baseline phase if less than 3 headache days were present during the 3 months baseline phase

Sample size calculation
The primary outcome was defined as a difference in reduction of headache days between the baseline and the follow-up period of ≥2 headache days in 12 weeks. The significance level α was set at 0.05 and the power at 0.9. Power size calculation with these parameters shows that a sample of \( n = 279 \) in the intervention group A (pediatric practice) and \( n = 507 \) children in the intervention group B (interdisciplinary treatment in social pediatric centers) is needed. For the sample size calculation an intra-class correlation coefficient (ICC) of 0.1 was assumed.

The estimated number for recruitment is based on an analysis of the Barmer insurance database of 2017 [1]. Approximately \( n = 270,000 \) statutorily insured children at the age of 6 to 11 years are likely to obtain a diagnosis of a primary headache disorder. About 70% of these see a pediatrician for primary care. As approximately 20% of pediatricians in practice use the website “PädExpert”, which provides the electronic migraine checklist, inclusion and exclusion criteria and access to the study platform, we calculated that \( n = 28,350 \) children per year are available for screening of migraine at the pediatric practices. We estimate that of these, 17.5% in fact receive a migraine diagnosis, resulting in \( n = 4961 \) children.

Germany was divided in 77 regions according to the postal codes, in a way that every postal code region contained at least one social pediatric center. The postal code regions were then randomized at a 2:1 ratio to intervention B and to intervention A regions. We estimated that in 75% of the intervention B regions at least one social pediatric center would be willing to participate in the study. We assumed that up to 20% of children will be excluded after the baseline phase or drop out later in the study: 1) because of more than 33% of missing data in the electronic headache diary during the baseline phase or 2) because of less than three documented headache days during the 3 months baseline or 3) because of more than 66% of missing data in the electronic headache diary during the follow-up period or 4) because they are lost to follow-up.

As shown in the flow chart (Fig. 1) the actual percentage of regions where at least one social pediatric center participated (intervention group B) was 73% (only slightly lower than estimated). Because of an assumed further drop out of 20% after recruitment, the numbers expected were \( n = 1931 \) and \( n = 1323 \) for the intervention B (social pediatric centers) and intervention A (pediatric practice) group respectively. These numbers exceed the required numbers as estimated in the power calculation. We chose a broad safety margin because of uncertainties related to the COVID-19 pandemic.

Study design
Overview (Fig. 2)
As described above, the study compares the pediatric practice treatment (intervention group A) and the interdisciplinary multimodal treatment (intervention group B). The timeline is illustrated in Fig. 2.

In both groups, children are diagnosed with migraine by their pediatrician in practice, included in the study and, if they have at least 3 days of headache in the baseline phase (week 12 to 0), go on to the intervention phase (week 0–12). The intervention phase includes treatment at the pediatric practice for both groups, and treatment at the social pediatric center only for the interdisciplinary multimodal group (intervention group B). There, children are treated with the structured multimodal interdisciplinary intervention “moma” as described below. After the intervention the follow-up
(week 12 to 24) is performed by the treating pediatrician in practice again.

Every participant has four study visits at the pediatric practice at time points −12, 0, 12 and 24 weeks. The interdisciplinary multimodal intervention group has three additional study (intervention) visits at the social pediatric centers.

At the first visit, the moma web application generates a hashcode for pseudonymization of the patient, which is given to the parents by the pediatrician. The parents use the hashcode to log into the "moma App", in which they document headache frequency, intensity and acute headache medication of their child on a daily basis.

---

**Fig. 1** Flow chart of the expected number of children with migraine treated by the interdisciplinary multimodal intervention in the social pediatric centers (intervention group B) and in the pediatric practice (intervention group A).

**Fig. 2** Study design, timelines and data acquisition.
Interdisciplinary multimodal intervention

The elements of the presented structured multidisciplinary intervention for children at the age of 6 to 11 years “moma” include:

1) pediatric elements such as exclusion of secondary causes and comorbidities by neurological examination and blood tests, and counselling regarding the bio-psycho-social model of pain,

2) physiotherapeutic elements such as examination of myofascial trigger points in the neck and shoulder muscles, education about the association of muscle tenderness and migraine and about individual exercise and self-administered stretching measures,

3) psychological elements such as evaluation of psychosocial circumstances, relevant psychological and behavioral factors for migraine, introduction of relaxation techniques and individual counselling to address the identified factors and improve self-efficacy.

The pathophysiological rationale for choosing these therapeutic elements is as follows:

According to epidemiological data, 45 to 85% of German adolescents with migraine (depending on migraine frequency) also suffer from muscle pain of neck or shoulders [9]. The pathophysiological explanation for this association is the concept of the trigemino-cervical complex (TCC) with its convergence of nociceptive afferents from cervical muscles to the caudal trigeminal nuclei [12]. As invasive or drug treatment is often not successful in young children, one focus of the presented intervention is on the cervical muscles as the easily accessible peripheral input of TCC [10]. With physiotherapeutic treatment of the muscle, including self-massage and stretching, the tenderness of the muscles is reduced which in our clinical experience leads to a decrease of headache frequency and/or intensity.

In addition, progressive muscle relaxation, which was shown to be effective in adults with migraine [13] was adapted for young children and is integrated in the psychological module of the presented intervention. Psychologists also screen for psychological stress and psychiatric comorbidities which are more frequent in patients with migraine compared to healthy persons [14]. The treated children are asked to draw their headache to visualize individual symptoms of migraine (Fig. 3) [15].

Measures

All outcome parameters are assessed via the dedicated smartphone application ‘moma app’, which is filled in by the parents over the 9 months study duration (Fig. 2).

The app contains the following features:

1. Headache diary (based on established diaries [16, 17]) including a daily reminder function (missed entries days can be catched up within 2 weeks), with daily assessment of the following items:

- Presence of headache (yes/no)
- Headache intensity (numeric rating scale 0–10 presented as a slider)
- Headache duration (slider from 0 to 24 h)
- Missed school (yes/no)
- Inability to perform leisure activities (yes/no)
- Use of headache medication (yes/no, tool for recording medication and dose)

2. Questionnaires are presented within the app at the start and end of the baseline (weeks – 12 and 0), at the end of the intervention (week 12) and at the end of the follow-up (week 24). The following questionnaires are used:
PedMIDAS (Pediatric Migraine Disability assessment score) [18]
KINDL [19] (German tool for assessing pediatric quality of life).

3. At the time points used for the questionnaires, the smartphone app also asks for

- typical triggers of headache in the last 3 months (within the categories: school stress, family problems, conflicts with friends, noise, sport, inactivity, weather, lack of sleep, drinks containing caffeine, reduced fluid intake, high use of electronic media, infection, others)
- headache prophylactic measures taken in the last 3 months (within the categories: physiotherapy, trigger point therapy, osteopathy, acupuncture, homeopathy, alternative practitioner, naturopathy, peppermint oil, magnesium, vitamin D, medication, others)

Additionally to the ‘moma App’, pediatricians in practice and social pediatric centers use the ‘moma website’ (www.moma-migraine.de) [1] to document the individual clinical presentation and characteristics of the child, for example individual migraine symptoms, important aspects of the medical history, results of the neurological examination, psychosocial factors and the therapeutic recommendations given to the family. Furthermore, they estimate the complexity of the disease for each child using the ‘moma complexity signature’, which has been developed by our group specifically for this study based on the bio-psycho-social model (see Fig. 3 for time points of data acquisition).

Outcome parameters
All outcome parameters are assessed via the parents’ entries in the ‘moma App’. For all outcome parameters, the difference from baseline to follow-up is measured and compared between the two groups.

The primary outcome parameter is the number of headache days per 12 weeks (84 days). Our hypothesis is that the reduction of headache days from baseline to follow-up will be at least 2 days larger for the group with interdisciplinary multimodal intervention in social pediatric centers (intervention group B) compared to the group with basic treatment in pediatric practices (intervention group A).

Secondary outcomes are:
1) Number of responders, defined as patients with a reduction of more than 50% of headache days per 12 weeks from baseline to follow-up;
2) Headache intensity (averaged over headache days per 12 weeks);
3) Number of days missed at school due to headache per 12 weeks;
4) Number of days with cancelling of leisure activities due to headache per 12 weeks;
5) Headache-related disability (PedMIDAS questionnaire) [18], assessed every 3 months;
6) Quality of life (KINDL questionnaire, every 3 months) [19, 20];
7) Number of days with intake of acute medication because of headache per 12 weeks.

Data analysis plan
The statistical analysis is performed according to the CONSORT Statement recommendations for cluster-randomized trials [20]. In the intention-to-treat analysis all patients having started to use the ‘moma App’ are included. Primary endpoint is the number of headache days per 12 weeks (84 days).

Two forms of analysis are performed:

1. Intention-to-treat analysis (“Full Analysis Set”)

All patients who started to use the electronic headache diary (moma app) and fulfill the baseline criteria (see below) are included in the intention-to-treat analysis. Patients who have less than three headache days during the 12 weeks of baseline or from whom less than 33% of the days of the headache diary are filled in during baseline are excluded and are not part of the intention-to-treat analysis.

2. On-treatment analysis (“per protocol set”)

Patients who additionally completed all 4 study visits at the pediatric practices and (only in the intervention group) the three visits at the social pediatric centers and provided electronic headache diary data with less than 33% of the days of the headache diary are filled in during baseline are excluded and are not part of the intention-to-treat analysis.
mean values of the the last 3-month period that has less than 33% missing data. If more than 66% of the data of the headache diary data is missing, a simple LOCF principle will be applied. For this, the data of the entire 3-month period will be replaced by the mean value of the last 3-month period with less than 33% missing data.

If one or more items of the PedMIDAS (6 items) is missing, the scale will be excluded from statistical analysis of this patient at this time point because it does not retain sufficient clinical informative value.

The KINDL questionnaire (4 subscales with 4 items each) allows one missing item per subscale which is replaced by the mean value of the other items of the subscale [19, 20].

For the primary end point (number of headache days per 12 weeks) a mixed linear regression model is performed with the difference of headache days per 12 weeks from baseline to follow-up as dependent variable, the intervention in a social pediatric center (yes/no) as independent variable and random effects for the different social pediatric centers. Age, sex and headache frequency per 12 weeks at baseline are included as possible confounders. Quality of life (KINDL) and migraine related disability (PedMIDAS) at baseline are possible effect modifying elements and therefore integrated in the model as interaction effects. The significance level \( \alpha \) is set at < 0.05. The same model is used for analysis of the secondary outcome parameters.

Discussion
Ethics, trial registration and data management
The study was approved by the local ethics committee at the Ludwig-Maximilians-University Munich (number 18–804, leading ethics committee) and approval was confirmed by all the other German ethics committees relevant for the study (\( n = 15 \)). The study was retrospectively registered on 27 April 2021 in the WHO approved German Clinical Trials Register (number DRKS00016698). Data protection is established according to the European data protection regulation 2016/679. Only the data necessary for study conduction and analysis is obtained via the smartphone app (from the parents) and via the moms website (from the pediatricians in practice and from the social pediatric centers). The study data is saved on a dedicated server located at the University of Hof, Germany. Data is pseudonymized at the time point of collection using a hash-code based on the patient’s name and birth date. This hash-code is only used to link data from the same patients on the server. It does not allow back-tracing of the patient’s name or birth date. The data will be stored for ten years.

Importance and dissemination
Migraine is a prevalent and disabling disease in childhood. Therapeutic options are scarce or not well tolerated by the children or their parents. Studies about the efficacy of non-invasive, non-pharmaceutical interdisciplinary treatment in young children with focus on the association of muscle tenderness and migraine do not exist so far. Hence, the presented intervention study is of high interest not only for the young patients but also for the pediatric and scientific communities as well as for the health systems worldwide. Therefore, we plan to publish the results of the multimodal intervention study in international scientific medical journals with a high distribution rate among pediatricians and neuropaediatricians. As the topic is also relevant for health politics, the results will also be published at the homepages or newsletters of relevant medical professional societies. The study outcomes will also be discussed at national and international congresses for (Neuro-) Pediatrics.

Strengths and limitations
The first strength of the study is the possible positive impact of the results for the participating child with migraine and its family. The second strength is the randomized controlled design with planned nationwide participation of pediatricians in practice and of interdisciplinary social pediatric centers. The third strength is the clinical and political importance of the study subject: interdisciplinary intervention programs for children with migraine are mandated but efficacy studies in this age group are lacking.

A limitation pertains to health system differences between countries, reducing generalizability of study results. The realization of study might be cumbersome because of challenges for pediatric practices related to the current COVID-19 pandemic.

Abbreviations
\( \alpha \): Significance level; App: Smartphone application; approx: Approximately; COVID-19: Coronavirus disease 2019; G-BA: Gemeinsamer Bundesausschuss = Federal Joint Committee; ICC: Intra-class correlation coefficient; ICD-10: International Classification of Diseases 10th revision; ICHD-3: International Classification of Headache Disorders 3rd edition; IQ: Intelligence quotient; KINDL: Name of a German tool for assessing pediatric quality of life; LOCF: Last observation carried forward; moma: Modules on migraine activity = name of the study; n: Number; NSAID: Nonsteroidal antiinflammatory drugs; PedMIDAS: Pediatric Migraine Disability Assessment Score; TCC: Trigemino-cervical complex; WHO: World Health Organization

Acknowledgements
We thank all children and parents for participating in this study as well as The Federal Joint Committee for funding.

Authors’ contributions
All authors have read and approved the manuscript. MNL contributed to the idea and to the concept of the study as well as to the definition of relevant outcome parameter and gave input to the study design based on her clinical expertise in pediatrics and in the care of children with migraine. She also participated in the development of the interdisciplinary structured intervention in the social pediatric centers and took part in the
communication with them and with the pediatricians in practice. Furthermore, she essentially contributed to the creation of the project website and App.FH contributed to the idea and to the concept of the study as well as to the definition of relevant outcome parameter and gave input to the study design according to his clinical expertise in pediatrics and in the care of children with migraine. He gave essential input in the development of the project tools and of the intervention at the social pediatric centers. LG contributed by discussing statistical, clinical and political relevance of the planned study and needed design changes. CK contributed in the development of the interdisciplinary structured intervention in the social pediatric centers based on her psychological expertise regarding children with migraine. Furthermore, she contributed to the creation of the project website and App RR contributed to the study design and definition of outcome parameters and in the conception and development of the moma App and website. AS contributed to the idea and to the concept of the study as well as to the definition of relevant outcome parameter and gave input to the study design according to his clinical expertise in neurology and in the care of adults with migraine. IS contributed to the development of the moma App and moma Website allowing the collection and analysis of data for interpreting study results. SwM contributed to the statistical calculations and to the achievement of all ethical approvals throughout Germany. VO contributed to the definition of outcome parameters, to the power and sample size calculation. RVK contributed to the idea and to the concept of the study as well as to the reflection, how to reach a study participation all over Germany based on his epidemiological expertise. He also contributed to the definition of relevant outcome parameter and to the power and sample size calculations. He developed the data analysis model and did the randomization according to the postal code zips. 

Funding
The German Federal Joint Committee, Innovation Committee (G-BA, Innovationsfonds, number 01NVF17044), funded the project upon which this publication is based (https://innovationsfonds.g-ba.de/service/). The funding body has no influence on the design of the study, on collection, analysis and interpretation of data and on writing the manuscript. Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the local ethics committee at the Ludwig-Maximilians-University Munich (number 18–804, leading ethics committee) and approval was confirmed by all the other German ethics committees relevant for the study (n = 15). A written informed consent is required from each child and parent for this study. The informed consent forms are stored at the treating pediatricians’ practice. The study was retrospectively registered on 27 April 2021 in the WHO approved German Clinical Trials Register (number DRKS00016698, https://www.drks.de/drks_web/navigate.do?navigationId=trialHTML&TRIAL_ID=DRKS00016698). The first version of the protocol, which is published here, was developed in 2017 and was not changed until now.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neuropediatrics, Developmental Medicine and Social Pediatrics, LMU Center for Development and Children with Medical Complexity – ISPZ Haunert, Dr. von Haunersches Kinderspital, Kinderklinik und Kinderpoliklinik der Ludwig Maximilians Universität, Munich, Munich, Germany. 2Department of Neurology, Ludwig-Maximilians-Universität, Munich, Munich, Germany. 3Hochschule Hof, Institute of Information Systems, Hof, Germany. 4Ludwig-Maximilians-Universität Munich, Institute for Social Pediatrics and Adolescent Medicine, Munich, Germany.

Received: 7 May 2021 Accepted: 6 June 2021
Published online: 30 June 2021

References
1. Moma project group Munich [Available from: https://www.moma-migraine.de, Accessed 22 June 2021.
2. Sillanpää M, Saarinen MM. Long term outcome of childhood onset headache: a prospective community study. Cephalalgia. 2018;38(6):1159–66. https://doi.org/10.1177/03331024177272536.
3. Diener H, Gaul C, Jensen R, Göbel H, Heinze A, Silberstein S. Integrated headache care. Cephalalgia. 2011;31(9):1039–47. https://doi.org/10.1177/0333102411409075.
4. Rohling S, Funk A, Ruscheweyh R, Schanken C, Straube A, Kamn K. Integrated headache care at the outpatient headache center of the University Hospital Munich: the Munich model. Clin Transl Neurosci. 2018;2:1–7.
5. Lernsta M, Stewart B, Olzynski WP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache. 2002;42(9):845–54. https://doi.org/10.1046/j.1526-4610.2002.02202.x.
6. Gurren-Steinpflle B, Greisinger N, Lang E, Muehlhans B, Stti R, Ulrich K. Effectiveness of an intensive multidisciplinary headache treatment program. Headache. 2009;49(7):990–1000. https://doi.org/10.1111/j.1526-4610.2009.01448.x.
7. Kropp P, Meyer B, Landgraf M, Ruscheweyh R, Ebinger F, Straube A. Headache in children: update on biobehavioral treatments. Neuropediatrics. 2013;44(1):20–4.
8. Mildke-Busch A, Blasche, A. Borggräfe I, Heinen F, Straube A, Von Kries R. Associations of diet and lifestyle with headache in high-school students: results from a cross-sectional study. Headache J Head Face Pain. 2010;50(7):1104–14. https://doi.org/10.1111/j.1526-4610.2010.01706.x.
9. Landgraf MN, von Kries R, Heinen F, Langhagen T, Straube A, Albers L. Self-reported neck and shoulder pain in adolescents is associated with episodic and chronic migraine. Cephalalgia. 2016;36(6):807–11. https://doi.org/10.1111/b headache_j_2610.
10. Larsson B, Carlton J, Fichtel Å, Melin L. Relaxation treatment of adolescent headache sufferers: results from a school-based replication series. Headache J Head Face Pain. 2005;45(6):692–704. https://doi.org/10.1111/j.1526-4610.2005.00518.x.
11. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(11):1–211.
12. Bartsch T, Goadby JP. Central mechanisms of peripheral nerve stimulation in headache disorders. Progress Neurol Surg. 2011;24:16–26. https://doi.org/10.1159/000323008.
13. Campbell JK; Penzien DW, EM. Evidence-based guidelines for migraine headaches: behavioral and physical treatments. 2000 [Available from: http://www.aan.com/professionals/practice/pdfs/gl0089.pdf.
14. Ebinger F, Burk A, Schmerzen bei Kindern und Jugendlichen, Ursachen, Diagnostik und Therapie Tiern, 2011. DOI https://doi.org/10.1056/NEJMoa1010037.
15. Broadbent E, Niederhofer K, Hague T, Cotter A, Reynolds L. Headaches sufferers’ drawings reflect distress, disability and illness perceptions. J Psychosom Res. 2020;66(5):465–70. https://doi.org/10.1016/j.psychores.2020.08.006.
16. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1–12. PMID: 2203666.
17. Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(11):115–25. https://doi.org/10.1056/NEJMoa1510384.
18. Hershey A, Powers S, Vockell A-L, LeCates S, Segers A, Kabbouche M. Development of a patient-based grading scale for PedsMIDAS. Cephalalgia. 2004;24(2):844–9. https://doi.org/10.1177/1468-2982.2004.02075.x.
19. Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res. 1998;7(5):399–407. https://doi.org/10.1023/A:1008853819715.
20. Ravens-Sieberer U, Bullinger M. Der Kindl-R Fragebogen zur Erfassung der gesundheitsbezogenen Lebensqualität bei Kindern und Jugendlichen-Revidierte Form. Diagnostische Verfahren zu Lebensqualität und Wohlbefinden; 2003: Hogrefe Göttingen.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.